Abstract. Post-menopausal osteoporosis is a bone formation disorder induced by estrogen deficiency. Estrogen deficiency facilitates the differentiation and maturation of osteoclasts by activating T lymphocytes. In our previous study, it was demonstrated that estrogen promotes bone marrow mesenchymal stem cell (BMMSC)-induced osteoclast apoptosis through down-regulation of microRNA (miR)-181a and subsequent Fas ligand (FasL) protein accumulation. In the present study, the regulatory effects of miR-181a on FasL expression in BMMSCs and the apoptotic effects of BMMSCs on cluster of differentiation (CD)4+T lymphocytes were investigated. An ovariectomized mouse model of osteoporosis (OVX) was established and CD4+T lymphocytes were isolated from the bones of these mice. The results demonstrated that the number of CD4+T lymphocytes was increased in the OVX group compared with the control group, thus suggesting that estrogen deficiency may increase CD4+T lymphocyte number. CD4+T lymphocytes were subsequently co-cultured with estrogen-treated BMMSCs, after which it was demonstrated that estrogen significantly promoted the apoptosis of CD4+T lymphocytes. Western blot analysis indicated that estrogen promoted the apoptosis of CD4+T lymphocytes through regulation of FasL expression in BMMSCs in a concentration-dependent manner. Finally, miR-181a was transfected into BMMSCs, which were co-cultured with CD4+T lymphocytes in vitro and in vivo. The results revealed that miR-181a exerted a negative regulatory effect on BMMSC-induced CD4+T lymphocyte apoptosis by regulating FasL protein expression in BMMSCs; this maybe a key mechanism underlying the development of estrogen deficiency-induced osteoporosis.

Introduction

Post-menopausal osteoporosis (PMO) is one of the most common types of osteoporosis. In 2008, the number of patients with PMO in China was estimated to be 100 million. The key symptoms of PMO include sex hormone disorder and immune imbalance, which leads to an imbalance between bone formation and bone resorption, where bone formation is significantly weakened (1). Clinical manifestations of PMO include a decrease in bone mass and deterioration of the bone microstructure, as well as an increase in bone brittleness, resulting in a higher fracture risk. The pathogenesis of PMO is well established; the disease is induced by estrogen deficiency as a result of ovarian function failure in post-menopausal women (2).

The regulatory effects of estrogen on bone metabolism occur through numerous mechanisms. For example, estrogen mediates the balance of bone resorption and bone formation by regulating parathyroid hormone. In addition, estrogen integrates with osteoblast receptors to promote bone formation. There are several growth factors involved in the regulatory effects of estrogen on bone metabolism, including interleukin (IL)-1, IL-6, IL-7, tumor necrosis factor (TNF)-α, transforming growth factor-β and interferon (IFN)-γ (3-6). Estrogen deficiency may directly or indirectly increase the number of B lymphocytes by increasing the expression levels of IL-7, of which promotes the expression of proinflammatory cytokines by T lymphocytes and macrophages, leading to bone mass loss (7,8). The inflammatory cytokines expressed by CD4+T lymphocytes have the most significant effects on bone cell function. CD4+T lymphocytes are divided into four...
main subpopulations: T helper (Th)1, Th2, Th17 cells promote osteoclast growth via the expression of receptor IFN-γ, IL-6, and IL-17 respectively (9). Among these four osteoclastogenic cytokines, RankL has a particularly important role in bone resorption. In vitro co-culture of murine bone marrow-derived pre-osteoclasts with CD4⁺ T lymphocytes leads to osteoclast differentiation and maturation (10). Emerging evidence has indicated an important role for estrogen in balancing osteoblasts and osteoclasts, through regulation of Fas/Fas ligand (FasL) signaling pathways. Fas is activated in response to FasL integration with the surface of cells expressing Fas. The activated Fas subsequently results in accumulation of adaptin in the cytoplasm by interaction of its intracellular death domain (DD) with the carboxyl terminal DD of the Fas-associated protein with death domain (FADD). The accumulated FADD integrates with caspase-8 through its death effect domain to form the death-inducing signaling complex, which activates the downstream caspase family and cell apoptosis (11,12). It has been revealed that estrogen can regulate the expression of FasL protein on the surface of osteoblasts and osteoclasts, causing osteoclast apoptosis by disrupting the bone dynamic balance (13,14).

Bone marrow mesenchymal stem cells (BMMSCs) are osteoblast precursor cells. It has been demonstrated that BMMSCs exert regulatory effects on immunocytes (10). BMMSCs may inhibit the growth of T lymphocytes at the G1/G0 stage of the cell cycle and suppress T lymphocyte proliferation (15,16). Furthermore, BMMSCs reduce the release of IFN-γ by activated T lymphocytes, and inhibit the proliferation and differentiation of B lymphocytes, natural killer cells and neutrophils (17). Previous research has indicated that BMMSCs have the ability to generate a variety of terminally differentiated mesenchymal cells, such as osteoblasts and chondrocytes, which are key in bone construction (18).

MicroRNAs (miRNAs/miRs) have several target genes and extensively participate in the gene regulatory network to exert various biological effects. Research suggests that miRNAs are key regulatory factors of the downstream network, to a greater extent than other regulatory factors and/or ligands (19). Previous work has indicated that miRNAs are key in the regulation of bone functional cell apoptosis. For example, miR-21 regulates expression of the FasL gene; therefore, the apoptotic rate of osteoclasts transfected with miR-21 is reduced, leading to the development of osteoporosis (20).

Our previous study demonstrated that BMMSCs induce osteoclast apoptosis in vitro and in vivo, and the addition of estrogen promotes BMMSCs-induced osteoclast apoptosis by increasing FasL protein expression. Further investigation revealed that estrogen maintains FasL protein accumulation by downregulating miR-181a expression (21). In the present study, CD4⁺ T lymphocytes were selected as a cell model to elucidate the regulatory effects of the signaling molecules involved in the development of osteoporosis (20). In vitro, the apoptosis rate of osteoclasts transfected with miR-21 is reduced, leading to the development of osteoporosis (20).

Materials and methods

Materials. α-Minimum Essential Media (MEM), RPMI-1640 and trypsin were purchased from Gibco (Thermo Fisher Scientific, Inc., Waltham, MA, USA). Goat anti-mouse CD45 (cat. no. ab65952), CD105 (cat. no. ab2529), stem cell antigen-1 (Sca-1; cat. no. ab25323) and CD29 (cat. no. ab17981) monoclonal antibodies were purchased from Abcam (Cambridge, MA, USA) and used for testing mesenchymal stem cells surface markers. CD3 (cat. no. 100243) and CD28 (cat. no. 102109) antibodies were purchased from BioLegend, Inc. (San Diego, CA, USA) and used for activation of T lymphocytes. Rabbit anti-mouse Fasl. (cat. no. sc-19988) and β-actin (cat. no. sc-69879) antibodies from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA) for FasL expression detection and normalization. Reagents for the induction of BMMSC differentiation, including dexamethasone, vitamin C, phosphate, β-phosphoglycerol, 3-isobutyl-1-methylxanthine (IBMX), insulin and transferrin were purchased from Sigma-Aldrich (Merck KGaA, Darmstadt, Germany). TR1Zol reagent, Lipofectamine® 2000 transfection reagent, miR-181a mimics, miR-181a inhibitor and miR-181a control were purchased from Invitrogen (Thermo Fisher Scientific, Inc.). GoldView™ nucleic acid gel stain (cat. no. 10201ES03) was purchased from Beijing SBSGenetech Co., Ltd. (Beijing, China). SYBR Green I Premix ExTaq™ (Cat. RR42LR), λ DNA-HindIII digest (cat. no. 3403), 50 bp DNA ladder (cat. no. 3421A), DL2000 DNA marker (cat. no. 3427A) and the miRNA assay kit (cat. no. 631435) were purchased from Takara Biotechnology Co., Ltd. (Dalian, China).

Mice osteoporosis model. All the experiments were performed on a total of 40 8-week-old female C57 mice (22-25 g), which were obtained from the Laboratory Animal Center of the Fourth Military Medical University (Xi’an, China). Bilateral ovaries were resected to establish the osteoporosis model within 20 mice (OVX group). The control group (n=20) were subjected to a similar surgery, with the exception that instead of ovary removal, a small amount of adipose tissue was removed (sham group). All mice were housed in a specific pathogen-free (SPF) environment (22°C, 12 h light/dark cycle, and 50-55% humidity) with free access to food and water. The present study was approved by the ethics committee of Chongqing Medical University (Chongqing, China).

Microtomography (Micro-CT). After 2 months maintenance in a SPF room, mice in the OVX and sham groups, or mimic BMMSCs, inhibitor BMMSCs and control BMMSCs groups were anaesthetized by intraperitoneal injection of pentobarbital sodium and placed on Micro-CT apparatus for an intraval scan of the proximal femoral area. The micro-CT scan was performed using a scanning angle of 360° and a resolution of 9 µm along the long axis of the femur. Following the Micro-CT scan, an area of 1 mm below the growth plate
and 1.5 mm from the distal femur was selected as the range of interest and a three-dimensional image of the trabecular bone was reconstructed. Finally, parameters representing the spatial structure of trabecular bone, including bone volume relative to tissue volume (BV/TV;%), trabecular thickness (Tb.Th; µm), trabecular spacing (Tb.Sp; mm) and trabecula number (Tb.N; 1/mm) were analyzed and determined using the built-in software (Inveon Research Workplace 2.2, Siemens Healthcare, Erlangen, Germany).

Isolation of CD4+ T lymphocytes. After 2 months maintenance in a SPF room, mice in the O VX and sham groups were anesthetized with 100 mg/kg pentobarbitonal sodium, decapitated and immersed in 75% alcohol with a temperature of 4°C for 5 min. The left abdomen skin of the mice was cut, and the subcutaneous tissue and abdominal muscles were separated to expose the spleen. Spleens were collected and peripheral connective tissues were removed, after which spleens were placed in PBS. Subsequently, the obtained spleens were minced and squeezed using tweezers under sterile conditions, in order to obtain a cell suspension. The cell suspension was transferred into sterile tubes and centrifuged at 400 x g for 3 min at 4°C. The supernatant was removed prior to the addition of 2 ml 1X Red Blood Cell Lysis Buffer (Beyotime Institute of Biotechnology, Haimen, China) at 4°C for 5 min for complete red blood cell lysis. The cell suspension was centrifuged again at 400 x g for 3 min in 4°C after which the supernatant was removed, and pellets were collected and washed twice with PBS. CD4 antibody (cat. no. 100413, purity ≥95% high-performance liquid chromatography; BioLegend, Inc.) was used for isolation of CD4+ lymphocytes. Monocyes were stained with fluorescent CD4+ antibody for 30 min at room temperature and without light. Finally, CD4+ T lymphocytes were obtained. To determine the concentration of CD4+ T lymphocytes, CD4+ T lymphocytes were fixed with 4% paraformaldehyde for 30 min at 4°C and a flow cytometer was used to count cell number and analyzed by equipped software (CytExpert 1.0.135.2, Beckman Coulter, Inc., Brea, CA, USA).

Isolation and subculture of BMMSCs. After 2 months maintenance in a SPF room, mice in the O VX and sham groups were anesthetized, decapitated and immersed in 75% alcohol at 4°C for 3 min. Mice were subsequently placed in a sterile glass dish, anterior and posterior limbs were separated, and surgery was performed to obtain the marrow cavity of the backbone. This was repeatedly washed in α-MEM until the color of the backbone became pale; the collected cell suspension contained the BMMSCs.

The obtained BMMSCs were seeded in 10-cm plastic petri dishes, containing α-MEM, 20% fetal bovine serum (FBS; Sijiqing Bioengineering Materials Co., Ltd, Hangzhou, China), 1% streptomycin and penicillin, cultured in an atmosphere of 37°C and 5% CO2. After 9 days, when BMMSCs had reached 70-80% confluence, cells were treated with 0.25% trypsin and subcultured at a ratio of 1:2. In the following passages, cell medium was refreshed every 2-3 days. When cells reached a confluence of 70-80%, cells were again treated with 0.25% trypsin and subcultured at a ratio of 1:2 or 1:3.

Determination of the immunophenotype of BMMSCs. The obtained third generation BMMSCs were dispersed in 200 µl PBS solution in an Eppendorf (EP) tube with a final concentration of 1x10⁶ cells per EP tube. Then, fluorescein isothiocyanate labeled anti-mouseSca-1 and CD29, and PE-labeled anti-mouseCD45 were added to the BMMSCs cell suspension and incubated in the dark at 4°C for 1 h. Subsequently, BMMSCs were washed 3 times with PBS solution containing FBS with a concentration of 30 ml/l, centrifuged at 400 x g for 5 min at 4°C Finally, the fluorescence-labeled BMMSCs were analyzed by flow cytometry. The positive rates of the cell surface antigen of BMMSCs were then analyzed and determined using the built-in software with the unit of %. (CytExpert 1.0.135.2, Beckman Coulter, Inc.).

Differentiation induction of BMMSCs. The obtained third generation BMMSCs were seeded in a 6-well plate with a concentration of 1x10⁶ cells/well. For the induction of differentiation, BMMSCs were either cultured in α-MEM with the addition of 20% FBS, 100 U/ml penicillin, 100 U/ml streptomycin or in osteoblast inducing conditional medium with 10 mM sodium glycerophosphate, 8M dexamethasone and 50 mg/ml vitamin C.

Alkaline phosphatase staining. After 7 days of differentiation induction, the cell medium was removed and the cells were washed 3 times with PBS. Then 4% paraformaldehyde solution was added to fix the cells for 20 min, followed by adding ALP staining solution (33 µl BCIP, 66 µl NBT and 10 ml PBS) and incubated in the dark for 30 min to 24 h. Following two washes with PBS, BMMSCs were imaged by phase-contrast microscopy. Note that the above protocols were strictly followed the instructions of the BCIP/NBT Alkaline Phosphatase Color Development kit (Beyotime Institute of Biotechnology.).

Calcified nodules staining. Following osteogenic induction for 21 days, BMMSCs were washed 3 times with PBS, fixed with 4% paraformaldehyde solution for 1 h, were washed twice again with PBS and finally stained with alizarin red for 15 min at room temperature. After complete removal of the excess alizarin red by three repeated washes with PBS, BMMSCs were imaged via phase-contrast microscopy (magnification, x400).

Adipogenic differentiation induction of BMMSCs. The third generation BMMSCs were seeded in a 6-well plate at a concentration of 1x10⁶ cells/well and incubated with α-MEM supplemented with 20%FBS 100 U/ml penicillin, 100 U/ml streptomycin, 8.9445 g indometacin, 27.8 g IBMX, 500 µl insulin (50 g/l) and 250 µlDex (39.1 g/l) for 14 days in 37°C. The cell culture medium was replaced every 2 days.

Oil red O staining. After 14 days following adipogenic differentiation, the cell medium was removed and cells were washed three times with PBS. Then, Oil Red O staining solution (0.5 g Oil Red O powder dissolved in 100 ml isopropanol) was added and incubated in the dark for 15 min. After removing the excess oil red O stain, cells were dispersed in PBS and imaged by the phase-contrast microscopy.
Co-culture of BMMSCs with CD4+ T lymphocytes. The primary CD4+ T lymphocytes derived from normal mice (lymphocytes derived from normal mice for co-culture with sham, OVX and estrogen-treated BMMSCs to observe the pro-apoptotic effect among the BMMSCs from three groups) were seeded in 24-well plates containing equal volume of α-MEM and RPMI-1640 medium at a final concentration of 1x10^6 cells/well at 37°C. Normal mice are the mice without sham or OVX operation, which are additional mice to the 40 stated above; the 40 mice stated above were used for osteoporosis or sham models. A total of 20 normal mice (8-weeks-old, 22-25 g, female) were obtained from the Laboratory Animal Center of the Fourth Military Medical University and housed under the same conditions as aforementioned. BMMSCs from each group (OVX, sham and estrogen-treated) were seeded at a concentration of 1x10^4 cells/well and co-cultured with CD4+ T lymphocytes in the same plate for 3 days. For estrogen treatment, the obtained third generation BMMSCs were washed twice with PBS and cultured in 10% FBS containing α-MEM without phenol red. When BMMSCs reached a confluency of 70-80%, estrogen with concentrations of 0, 0.1, 1, 10 and 100 nM were added to the cell medium for 24 h for activation. BMMSCs from each group (OVX, sham and estrogen-treated) were washed with 2-3 ml PBS at 4°C and centrifuged for 5 min at 400 x g (4°C). The resultant cell pellets were collected, washed and dispersed in PBS solution containing 7-aminoactinomycin D (7AAD) and anti-mouse CD4 staining antibodies (Invitrogen cat. no. 100413) was added and incubated at 4˚C in the dark for 1 h. AnnexinV (5 µl) and 7AAD (5 µl) were subsequently added and the whole system was incubated in the dark at room temperature for 15 min. Finally, the apoptotic ratio of CD4+ T lymphocytes was detected using the Annexin V , fluorode membranes (EMD Millipore, Billerica, MA, USA).

Detection of CD4+ T lymphocyte apoptosis. CD4+ T lymphocyte apoptosis was detected using the Annexin V, 7-aminoactinomycin D (7AAD) and anti-mouse CD4 staining method. Briefly, after 3 days of BMMSCs and CD4+ T lymphocyte co-culture, supernatants were collected and centrifuged at 12,000 x g with a duration of 5 min at 4˚C and the supernatant was subsequently treated with 1X cell lysis buffer (Beyotime Institute of Biotechnology) according to the instructions provided within the Nuclear and Cytoplasmic Protein Extraction kit (Beyotime Institute of Biotechnology). Suspensions were centrifuged for 3-5 min. Finally, 20 µl DEPC was added to dissolve the RNA samples. The membranes were blocked with 5% bovine serum albumin (BSA) blocking buffer (Sigma-Aldrich, Merck KGaA) and then were incubated overnight at 4°C with the primary antibodies (FasL and β-actin, 1:50 dilution). The membranes were then incubated with goat anti-rabbit IgG (H+L) secondary antibody (unconjugated) (Wuhan Boster Biological Biological Technology, Ltd., Wuhan, China) at room temperature for 2 h. The blots on the membranes were analyzed using imaging system (WD-9423C, Beijing Liuyi Biotechnology, Co., Ltd., Beijing, China) under treatment of an enhanced chemiluminescence kit (GE Healthcare, Chicago, IL, USA).

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Total RNA was extracted from OVX, Sham and estrogen-treated BMMSCs. Total RNA was isolated using TRIzol reagent according to the manufacturer's protocols. miR-181aprimers were designed and synthesized by Guangzhou RibioBio Co., Ltd. (Guangzhou, China); sequences are listed in Table I. The PCR reaction mixture included: SYBR® Green Mix (10 µl), RT template (2 µl), Bulge-Loop™ miRNA forward (1 µl; 5 µM), Bulge-Loop™ miRNA reverse (1 µl; 5 µM) and RNase-free H2O (5 µl). The thermocycling conditions were as follows: Initial denaturation at 95°C for 3 min, followed by 40 cycles of denaturation at 95°C for 30 sec, annealing for 30 sec and extension at 72°C for 30 sec. The fluorescent signals were recorded during the extension process and the data were analyzed using the dissolution curve (95°C for 15 sec, 60°C for 23 sec and 95°C for 15 sec) at the end of all cycles. The data were normalized using 2^(-∆∆Cq) (23).

RNA extraction. A total of 1 ml TRIzol was added to each well; 2x10^6 cells were incubated for 6 min. The lysis solution was then transferred to 1.5 ml EP tube with the addition of 0.2 ml chloroform. The tube was shaken vigorously for 15 min and incubated at 15-30°C for 2-3 min, followed by centrifugation at 10,000 x g for 15 min at 4°C. After careful removal of the upper layer into a new EP tube, an equal volume of isopropanol was added, and the EP tube was placed in the -20°C fridge without disturbance for 1 h, then centrifuged at 10,000 x g for 15 min at 4°C. After removing the supernatant, 500 µl 75% ethanol was added to disperse the precipitates and gently mixed for 30 sec, followed by centrifugation at 10,000 x g for 5 min at 4°C. The resultant supernatant was removed and the precipitates in the tube were dried under RNase free condition for 3-5 min. Finally, 20 µl DEPC was added to dissolve the dried precipitates and the RNA solution was saved in a fridge under -80°C.

RNA detection. A total of 2 µl of the aforementioned obtained RNA solution with 1 µl buffer and then 1.5% agarose gel electrophoresis was used for RNA detection at a voltage of 80 V. After 30 min run in a fresh 1X TBE buffer, band 185 and 285 representing RNA sample in the gel were detected by equipped software (CytExpert1.1, Beckman Coulter, Inc.).
UV transmission detector. Finally, the RNA concentration was determined using an EP RNA detector.

**RNA reverse transcription.** The reaction solution was prepared according to the instructions of Bulge-loop™ miRNA-qRT-PCR Primer containing 10 µl 2X miRNA Reaction Buffer Mix (RT), 2 µl 0.1%BSA, 2 µl miRNA PrimeScriptRT Enzyme Mix, 1 µl total RNA, and 5 µl RNase Free ddH2O. The prepared reaction solution was placed in the PCR amplifier for RT: 42˚C, 60 min and 70˚C, 10 min for 40 cycles. Subsequently, cDNA derived from sham, OVX and estrogen-treated BMMSCs was collected and placed on ice for microRNA detection.

**miR-181a cell transfection.** A total of 1 day prior to transfection, the appropriate number of BMMSCs was seeded into the wells of a culture plate, and cells were cultured in α-MEM without antibiotics until cell confluence reached 30-50%. Cell density is a key factor that affects transfection efficiency, and cell overgrowth weakens their activity and reduces transfection efficiency. miRNA mimic (miR10000858-1-5), inhibitor (miR20000858-1-5), control (miR30017138-1-10) (1.25 µl) and Lipofectamine® 2000 were separately diluted with 50 µl serum-free α-MEM, mixed gently and incubated at room temperature for 5 min for further use. The diluted solutions were mixed gently and incubated at room temperature for 20 min. The prepared transfection solution was added to the bottom of each well of the 12-well plate and 5x10^4 cells/well were added. The cells were incubated at 37°C for 24 h. miR-181a mimic, inhibitor or control-transfected BMMSCs were also used for intravascular injection at a dose of 5x10^6 cells. After 5 days following the administration of transfected BMMSCs, the in vivo lymphocytes were collected and used for apoptosis analysis by flow cytometry as aforementioned.

**Statistical analysis.** Statistical analysis was performed using SPSS11.0 software (SPSS, Inc., Chicago, IL, USA). Comparison of multiple groups was performed using one way analysis of variance followed by a Tukey's post-hoc test. The means of two independent samples were compared using Student's t-test. P<0.05 was considered to indicate a statistically significant difference.

**Results**

**Isolation and identification of BMMSCs.** A mouse model of osteoporosis was established and verified by Micro-CT analysis (Table II). BMMSCs were subsequently isolated from the mice in the OVX and sham groups, and their immunophenotype and multi-potent differentiation abilities were examined. The obtained BMMSCs were revealed to possess stem cell-like characteristics and multi-potent differentiation ability (data not shown).

**Comparison of CD4+ T lymphocyte numbers in each group.** A previous study indicated that estrogen deficiency activates T lymphocytes and disrupts the dynamic balance between bone resorption and formation (8). Therefore, in the present study, CD4+ T cells were isolated from mice in the sham (Fig. 1A and B) and OVX groups (Fig. 1C and D), and cell numbers were determined by flow cytometry. As shown in Fig. 1E, the percentage of CD4+ T lymphocytes was determined in total spleen cells. The number of CD4+ T lymphocytes in the OVX group was markedly higher compared within the Sham group, thus suggesting that estrogen deficiency may increase the number of CD4+ T lymphocytes.

**Apoptotic effects of estrogen-treated BMMSCs on CD4+ T lymphocytes.** Our previous work demonstrated that BMMSCs induce osteoclast apoptosis and estrogen promotes BMMSCs-induced osteoclast apoptosis (18). In the present study, the apoptotic effects of BMMSCs on CD4+ T lymphocytes were examined. Isolated BMMSCs from the OVX group were activated by treatment with estrogen at various concentrations. Estrogen-treated BMMSCs were co-cultured with CD4+ T lymphocytes for 3 days (OVX+ estrogen group) and CD4+ T lymphocyte apoptosis in the co-culture system was subsequently determined. As a control, CD4+ T lymphocytes were co-cultured with untreated BMMSCs from the OVX and sham groups, and the apoptotic rate was determined. Annexin V was used to label early apoptotic and necrotic cells, 7AAD was used to label late apoptotic and necrotic cells, and anti-mouse CD4 antibody was used to specifically investigate CD4+ T lymphocytes. The flow cytometry results of the OVX (Fig. 2A), sham (Fig. 2B) and OVX+E2 groups (Fig. 2C) revealed that the apoptotic rate of CD4+ T lymphocytes in the OVX+E2 group was markedly higher, compared with that in the sham or OVX groups. The apoptotic rate of CD4+ T lymphocytes in the OVX group was the lowest among the three groups (Fig. 2D). These results suggested that BMMSCs may have an apoptotic effect on CD4+ T lymphocytes and that estrogen significantly increased this effect.

Table I. Oligonucleotide primers used for polymerase chain reaction.

| Primer         | Sequence                        | Product size (bp) | Tm   |
|----------------|---------------------------------|-------------------|------|
| MicroRNA-181a  | F: 5'-AACATTCAACGCTGTCGGTGAGT-3' | 118               | 62˚C |
|                | R: 5'-CTCCCTTAGAATCTGTTGTGCTCTCATA-3' |                  |      |
| U6             | F: 5'-CTCGCTTTCGCGACGACA-3'     | 88                | 60.6˚C|
|                | R: 5'-AAGCCTTCAGAATTGCGT-3'     |                  |      |

bp, base pairs; F, forward; R, reverse; Tm, primer melting temperature.
Table II. Microtomography results of the sham and OVX groups.

| Group | BV/TV (%) | BS/BV (1/mm) | Tb.Th (mm) | Tb.N (1/mm) | Tb.Sp (mm) | BMD (mg/cc) |
|-------|-----------|--------------|------------|-------------|------------|-------------|
| Sham  | 21.15±3.42| 25.34±3.12   | 0.840±0.08 | 2.01±0.4    | 0.41±0.11  | 408.80±21.55|
| OVX   | 5.32±1.65a| 8.98±4.05b   | 0.051±0.02a| 0.42±0.6b   | 0.82±0.16b | 60.45±18.79 |

*P<0.01, *P<0.05 vs. the sham group. BMD, bone mineral density; BS/BV, bone surface relative to bone volume; BV/TV, bone volume relative to tissue volume; OVX, bilateral ovariectomy group; Tb.N, trabecular bone number; Tb.Sp, trabecular bone spacing; Tb.Th, trabecular bone thickness.

Figure 1. Flow cytometry was used to detect CD4+ T lymphocytes in the (A and B) sham and (C and D) OVX groups; cell debris was excluded. (E) The percentage of CD4+ T cells were increased within OVX mice compared to Sham mice. CD4, cluster of differentiation 4; OVX, bilateral ovariectomy group.

Figure 2. Flow cytometric analysis of CD4+ T lymphocyte apoptosis in the (A) OVX, (B) sham and (C) OVX+E2 groups. (D) Comparison of the apoptotic rates of CD4+T lymphocytes in each group. 7AAD, 7-aminoactinomycin D; CD4, cluster of differentiation 4; E2, estrogen; OVX, bilateral ovariectomy group.
miR-181a expression in BMMSCs. It has previously been reported that miRNAs are important in the regulation of BMMSC function. According to a previous study it was demonstrated that miRNA-21 expression is decreased in BMMSCs following surgical ovariectomy (25). In addition, it has been demonstrated that miR-181a expression is significantly increased in an OVX group (18). In the present study, the expression levels of miR-181a in the three different co-culture systems were determined by RT-qPCR. miR-181a expression was significantly higher in the OVX group compared with in the sham group (Fig. 4A). Conversely, estrogen treatment decreased miR-181a expression in BMMSCs in a concentration-dependent manner; however, when estrogen concentration reached 100 nM, miR-181a expression was increased to some extent compared with the levels detected following treatment with 10 nM estrogen, thus indicating that excessive estrogen may exert an inverse effect (Fig. 4B).

Effects of miR-181a transfection on FasL expression in BMMSCs. miR-181a was transfected into BMMSCs to determine the regulatory effects of miR-181a on FasL protein expression in BMMSCs. BMMSCs were transfected with miR-181a mimic, mimic control, mimic control, miR-181a inhibitor or inhibitor control. The transfection efficiency of the miR-181a mimic and the miR-181a inhibitor was confirmed by RT-qPCR. Compared with in mimic control group, the expression levels of miR-181a were increased by ~50-fold in BMMSCs transfected with the miR-181a mimic (Fig. 4C), whereas miR-181a expression was ~15 times lower in BMMSCs transfected with the miR-181a inhibitor compared with the inhibitor control (Fig. 4D). These data suggested that the miR-181a mimic and miR-181a inhibitor were transfected into BMMSCs with high efficiency.

Western blot analysis was subsequently performed to detect FasL protein levels in each group. FasL protein expression in BMMSCs transfected with the miR-181a mimic was markedly inhibited compared with in mimic control group, whereas a significant increase in FasL protein expression was detected in BMMSCs transfected with the miR-181a inhibitor compared with the inhibitor control (Fig. 4E).

In vitro regulatory effect of miR-181a on CD4+ T lymphocyte apoptosis. Our previous work revealed a negative regulatory effect of miR-181a on BMMSCs-induced osteoclast apoptosis (18). Therefore, the regulatory effects of miR-181a on BMMSC-induced CD4+ T lymphocyte apoptosis were examined in the present study. BMMSCs were transfected with miR-181a mimic, mimic control and miR-181a inhibitor. The transfected BMMSCs were subsequently co-cultured with CD4+ T lymphocytes, in order to determine their apoptotic effect on CD4+ T lymphocytes. Flow cytometric analysis revealed that miR-181a mimic transfection resulted in a significant reduction in the proportion of apoptotic cells (5.1%; Fig. 5A) compared with in the control group (11.0%; Fig. 5B); however, miR-181a inhibitor transfection resulted in an increased number of apoptotic cells (24.0%; Fig. 5C), thus indicating the regulatory effect of miR-181a on BMMSC-induced CD4+ T lymphocyte apoptosis (Fig. 5D).

In vivo regulatory effect of miR-181a on CD4+ T lymphocyte apoptosis. To validate the in vivo regulatory effects of miR-181a on CD4+ T lymphocyte apoptosis, BMMSCs transfected with miR-181a mimic, mimic control and miR-181a inhibitor were intravenously injected into mice. After 7 days of treatment, alterations in mouse bone content were determined by micro-CT. The bone volume of mice treated with the miR-181a mimic (Fig. 6A) was markedly lower compared with in the control group (Fig. 6B). Conversely, mice in the miR-181a inhibitor group (Fig. 6C) had a visibly higher bone volume than the control group. The derive parameters from the micro-CT measurements (Table III) further confirm these findings; bone mass measurements, including BV/TV, BS/BV and BMD, were significantly decreased in the miR-181a mimic-treated group compared with in the control group. Conversely, the opposite effect was observed in the group treated with the miR-181a inhibitor.

Furthermore, alterations in the apoptotic rate of CD4+ T lymphocytes were detected after 2 days of injection with BMMSCs transfected with miR-181a mimic, mimic control and miR-181a inhibitor. The apoptotic rate of CD4+ T lymphocytes in mice treated with the miR-181a mimic (Fig. 4D) was markedly decreased compared with in the control group (Fig. 4E), whereas apoptosis was markedly increased in the miR-181a inhibitor-treated group (Fig. 6F), which further demonstrated the effects of miR-181a on CD4+ T lymphocyte apoptosis (Fig. 6G).

Discussion
It has previously been reported that PMO is a bone formation disorder caused by estrogen deficiency (14). Estrogen
Estrogen deficiency facilitates the differentiation and maturation of osteoclasts by inducing the expression of RankL/Rank in T lymphocytes (26). The results of the present study demonstrated that estrogen affected BMMSC-induced apoptosis of CD4+ T lymphocytes. The present study also suggested that the regulatory effects of estrogen on BMMSC-induced CD4+ T lymphocyte apoptosis may be mediated by FasL protein expression in BMMSCs, with estrogen increasing FasL protein expression. However, no difference in FasL protein expression was detected in BMMSCs when estrogen concentration reached 100 nM compared with 10 nM treatment. This may be due to the presence of an estrogen response element (ERE) on the promoter sequence of the FasL gene, which integrates with the estrogen-activated estrogen receptor (ER) to promote gene expression of FasL. (27); when estrogen concentration is too high, the integration ability between ERE and ER may be weakened, thus reducing the regulatory effect of estrogen on FasL expression (28).

Estrogen has been reported to affect miRNA expression in zebrafish, mice and ACI rats (29,30). It has been revealed that estrogen inhibits osteoblast apoptosis through upregulation of miR-17-92a (31). In addition, estrogen treatment results in the increased expression of miR-146a, miR-125a, miR-125b, let-7e and miR-126 in T lymphocytes isolated from mouse spleen (32). Previous studies have suggested that miR-181a is involved in cell differentiation and development, as well as immunological, cardiovascular and central nervous system diseases (33-35). In the present study, miRNAs that upregulate BMMSCs in mice with osteoporosis were selected using genechips, and miR-181a was selected as the miRNA of interest based on miRNA target gene prediction software.

The present study observed that miR-181a expression in BMMSCs was markedly increased in the OVX group, which may be due to the decrease in estrogen during the development of osteoporosis following ovary removal. Conversely, the expression levels of miR-181a were significantly reduced in BMMSCs treated with estrogen at a concentration of 0.1, 1 and 10 nM, thus demonstrating the negative regulatory effect of estrogen on miR-181a expression within a certain concentration range. In addition, a significant decrease in CD4+T lymphocyte apoptosis was observed following the
upregulation of miR-181a expression; this may be due to the inhibited expression of CD4+ T lymphocyte apoptosis-associated factors in BMMSCs, including FasL. By performing western blot analyses, it was revealed that the expression levels of the apoptotic protein, FasL, were reduced in BMMSCs following miR-181amimic transfection. In conclusion, it may be suggested that miR-181 affects BMMSCs-mediated apoptosis of CD4+ T lymphocytes via the regulation of FasL protein expression; this regulatory ability may be directly associated with estrogen concentration. A previous study reported similar results, that estrogen induces the expression of B-cell lymphoma 2, cyclin D1 and survivin by inhibiting the expression of miR-6, miR-143 and miR-203 in MCF-7 cells. In addition, the regulatory effects of estrogen are eliminated by estrogen inhibitors (36). In addition, further study may be conducted to investigate the downstream signaling underlying miR-181a/FasL to understand mechanism of osteoporosis and to develop a novel therapy for osteoporosis, by potentially targeting the regulation of miR-181a.

Acknowledgements

The authors would like to thank the Chongqing Municipal Key Laboratory of Oral Biomedical Engineering of Higher Education and the Program from Innovation Team Building at Institutions of Higher Education of Chongqing, 2016 for support of basic medicine research. The authors would also thank to Miss Hua Ni for molecular and cellular experiments assistance, and thank Mr. Xiaolin Xu for assisting with the animal experiments (Research and Development Center for Tissue Engineering, Fourth Military Medical University (Xi’an, China).

Funding

This research was funded by the General Program of National Natural Science Foundation of China (grant no. 31571508) and the General Program of National Natural Science Foundation of China (grant no. 31371473).

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Author’s contributions

BS made substantial contributions to the conception and design, collection and assembly of data, data analysis and interpretation, wrote the manuscript. XF made substantial contributions to the design of the present study, collection, analysis and interpretation of data; YY made contributions in modifying the study design, assembly of data and data analysis and interpretation. DY made substantial contributions to the conception and design of the present study, data analysis and interpretation, wrote the manuscript and gave final approval.
Table III. Microtomography results of the mice treated with microRNA-181a mimic, inhibitor or control for 7 days.

| Group    | BV/TV (%) | BS/BV (1/mm) | Tb.Th (mm) | Tb.N (1/mm) | Tb.Sp (mm) | BMD (mg/cc) |
|----------|-----------|--------------|------------|-------------|------------|-------------|
| Mimic    | 5.15±3.02 | 25.34±3.12   | 0.04±0.08  | 2.01±0.4    | 0.91±0.11  | 150.80±21.55|
| Control  | 10.32±1.65 | 30.98±4.05   | 0.51±0.02  | 4.42±0.6    | 0.71±0.16  | 250.45±16.09|
| Inhibitor| 19.45±3.42 | 28.31±3.10   | 0.84±0.08  | 2.01±0.4    | 0.41±0.11  | 370.80±21.55|

\(^aP<0.01\) (compared to mimic), \(^bP<0.05\) (compared to mimic)

BMD, bone mineral density; BS/BV, bone surface relative to bone volume; BV/TV, bone volume relative to tissue volume; Tb.N, trabecula number; Tb.Sp, trabecular spacing; Tb.Th, trabecula thickness.

Figure 6. Representative microtomography images of mouse bone and analysis of CD4^+^ T lymphocyte apoptosis. Mice were treated with BMMSCs transfected with (A) miR-181a mimic, (B) mimic control or (C) miR-181a inhibitor. Flow cytometric analysis of apoptosis of CD4^+^ T lymphocytes from mice treated with (D) miR-181a mimic, (E) mimic control or (F) miR-181a inhibitor. (G) Comparison of the apoptotic rate of CD4^+^ T lymphocytes in each group. 7AAD, 7-aminoactinomycin D; BMMSCs, bone marrow mesenchymal stem cells; CD4, cluster of differentiation 4; miR-181a, microRNA-181a.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.
References

1. Rachner TD, Khosla S and Hofbauer LC: Osteoporosis: Now and the future. Lancet 377: 1276-1287, 2011.

2. Weitzmann MN and Pacini R: Estrogen deficiency and bone loss: An inflammatory tale. J Clin Invest 116: 1186-1194, 2006.

3. Roggia C, Gao Y, Cenci S, Weitzmann MN, Toraldo G, Isaia G and Pacini R: Up-regulation of TNF-producing T cells in the bone marrow: A key mechanism by which estrogen deficiency induces bone loss in vivo. Proc Natl Acad Sci USA 98: 13960-13965, 2001.

4. Duque G, Huang DC, Dion N, Macoritto M, Rivas D, Li W, Yang XF, Li J, Lian J, Marino FT, et al: Interferon-gamma plays a role in bone formation in vivo and rescues osteoporosis in ovariectomized mice. J Bone Min Res 26: 1472-1483, 2011.

5. Cenci S, Toraldo G, Weitzmann MN, Roggia C, Gao Y, Qian WP, Sierra O and Pacini R: Estrogen deficiency induces bone loss by increasing T cell proliferation and lifespan through IFN-gamma-induced class II transactivator. Proc Natl Acad Sci USA 100: 10405-10410, 2003.

6. Kudo O, Sabokbar A, Pocock A, Itonaga I, Fujikawa Y and Athanasou NA: Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. Bone 32: 1-7, 2003.

7. Hartgring SAY, Bijlsma JWJ, Lafeber FPJG and van Roon JAG: Bone marrow mesenchymal stem cells inhibit the T-cell proliferation and cytokine expression of collagen-induced arthritis. Arthritis Res Ther 12: R31, 2010.

8. Schurgers E, Kelchtermans H, Mitera G, Teboul A, Cuvellier S, and Harel-Bellan A: The role of mesenchymal stromal cells is mediated by T cells. Stem Cells 24: 93-103, 2006.

9. Lynch D, Tsien RY and Lenardo MJ: Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic Fas ligand. EMBO J 27: 535-545, 2008.

10. Ceniceros M, Groisman R, Souidi M, Cuvellier S, and Harel-Bellan A: The RANKL-induced class II transactivator. Proc Natl Acad Sci USA 96: 3540-3545, 1999.

11. Kovalchuk O, Tryndyak VP, Montgomery B, Boyko A, Kutanzi K, Zemp F, Warbritton AR, Latendresse JR, Kovalchuk I, Beland FA, Nilsen J, Brown W, Song J and Naftolin F: Regulation of Fas ligand expression in breast cancer cells by estrogen: Functional differences between estradiol and tamoxifen. J Steroid Biochem Mol Biol 73: 185-194, 2003.

12. Cohen A, Shmoish M, Levi L, Cherutti U, Levavi-Sivan B and Lubzens E: Alterations in ribosomal RNA and ribonucleic acid expression profiles reveal a novel pathway for estrogen regulation. Endocrinology 149: 1687-1696, 2008.

13. Kovalchuk O, Tryndyak VP, Montgomery B, Boyko A, Kutanzi K, Zemp F, Warbritton AR, Latendresse JR, Kovalchuk I, Beland FA, Nilsen J, Brown W, Song J and Naftolin F: Regulation of Fas ligand expression in breast cancer cells by estrogen: Functional differences between estradiol and tamoxifen. J Steroid Biochem Mol Biol 73: 185-194, 2003.

14. Cohen A, Shmoish M, Levi L, Cherutti U, Levavi-Sivan B and Lubzens E: Alterations in ribosomal RNA and ribonucleic acid expression profiles reveal a novel pathway for estrogen regulation. Endocrinology 149: 1687-1696, 2008.

15. Kovalchuk O, Tryndyak VP, Montgomery B, Boyko A, Kutanzi K, Zemp F, Warbritton AR, Latendresse JR, Kovalchuk I, Beland FA, Nilsen J, Brown W, Song J and Naftolin F: Regulation of Fas ligand expression in breast cancer cells by estrogen: Functional differences between estradiol and tamoxifen. J Steroid Biochem Mol Biol 73: 185-194, 2003.

16. Cohen A, Shmoish M, Levi L, Cherutti U, Levavi-Sivan B and Lubzens E: Alterations in ribosomal RNA and ribonucleic acid expression profiles reveal a novel pathway for estrogen regulation. Endocrinology 149: 1687-1696, 2008.

17. Kovalchuk O, Tryndyak VP, Montgomery B, Boyko A, Kutanzi K, Zemp F, Warbritton AR, Latendresse JR, Kovalchuk I, Beland FA, Nilsen J, Brown W, Song J and Naftolin F: Regulation of Fas ligand expression in breast cancer cells by estrogen: Functional differences between estradiol and tamoxifen. J Steroid Biochem Mol Biol 73: 185-194, 2003.

18. Cohen A, Shmoish M, Levi L, Cherutti U, Levavi-Sivan B and Lubzens E: Alterations in ribosomal RNA and ribonucleic acid expression profiles reveal a novel pathway for estrogen regulation. Endocrinology 149: 1687-1696, 2008.

19. Kovalchuk O, Tryndyak VP, Montgomery B, Boyko A, Kutanzi K, Zemp F, Warbritton AR, Latendresse JR, Kovalchuk I, Beland FA, Nilsen J, Brown W, Song J and Naftolin F: Regulation of Fas ligand expression in breast cancer cells by estrogen: Functional differences between estradiol and tamoxifen. J Steroid Biochem Mol Biol 73: 185-194, 2003.

20. Cohen A, Shmoish M, Levi L, Cherutti U, Levavi-Sivan B and Lubzens E: Alterations in ribosomal RNA and ribonucleic acid expression profiles reveal a novel pathway for estrogen regulation. Endocrinology 149: 1687-1696, 2008.

21. Kovalchuk O, Tryndyak VP, Montgomery B, Boyko A, Kutanzi K, Zemp F, Warbritton AR, Latendresse JR, Kovalchuk I, Beland FA, Nilsen J, Brown W, Song J and Naftolin F: Regulation of Fas ligand expression in breast cancer cells by estrogen: Functional differences between estradiol and tamoxifen. J Steroid Biochem Mol Biol 73: 185-194, 2003.

22. Cohen A, Shmoish M, Levi L, Cherutti U, Levavi-Sivan B and Lubzens E: Alterations in ribosomal RNA and ribonucleic acid expression profiles reveal a novel pathway for estrogen regulation. Endocrinology 149: 1687-1696, 2008.